Life Science & Biotech

Marcadia may fetch up to $537 million in sale

February 2, 2011
J.K. Wall
The December sale of Carmel-based Marcadia Biotech to Roche garnered at least $287 million—and as much as $537 million—for the company’s owners and could lead the Marcadia management team to launch a firm using one of Marcadia’s experimental diabetes medicines.
More

Molecules are moneymakers for software firm Indigo BioSystemsRestricted Content

January 29, 2011
Chris O'Malley
Eli Lilly and Co. spin-off has landed new private investment and may double its work force this year.
More

Marketing firm VMS plans growth, new jobs

January 28, 2011
 IBJ Staff
Event-planning powerhouse VMS Inc. plans to invest more than $1.5 million to expand its Indianapolis life sciences marketing operation and create as many as 102 jobs over the next four years, state officials said Friday morning.
More

Life sciences to drive Purdue's next decade of building

January 26, 2011
J.K. Wall
Over the past 10 years, Purdue University has built Discovery Park into a thriving research and business incubation center, launching more than 30 companies and hosting dozens more. Now Purdue will spend more than $164 million to construct a Life and Health Sciences Quadrangle next to Discovery Park.
More

Lilly imaging drug fails to win FDA panel's backing

January 21, 2011
Bloomberg News
Eli Lilly and Co.'s Amyvid isn't ready to be approved to detect Alzheimer's-related deposits in the brain, according to FDA advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results of brain scans are read consistently, they said.
More

Down on luck, Lilly finds comfort in pets

January 19, 2011
J.K. Wall
Eli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
More

Endocyte prices IPO stock

January 14, 2011
J.K. Wall
The West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch $80 million to $92 million.
More

Panel says Lilly’s Solpura isn’t ready for approval

January 12, 2011
Bloomberg News
Eli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that isn’t derived from pig parts.
More

Roche back in court as partner looks to sell to competitor

January 12, 2011
J.K. Wall
Roche Diagnostics requested a temporary restraining order against Medical Automation Systems Inc. Tuesday after receiving word the company is speeding up plans to sell itself to Roche rival Alere Inc.
More

Deal could give Lilly full diabetes deck

January 12, 2011
J.K. Wall
Eli Lilly and Co.'s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy that some consultants think is key to pharma companies’ futures.
More

UPDATE: Analysts praise Lilly diabetes deal with Boehringer

January 11, 2011
J.K. Wall
The deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with five drugs and payments to be named later—but analysts and investors generally liked what they heard.
More

Aprimo sale may usher in 'new wave' of tech dealsRestricted Content

January 8, 2011
Chris O'Malley
Observers say conditions are ripening for more deals like the recent $525 million sale of Aprimo Inc. in the months ahead—not only among IT firms, but also among biotech companies here.
More

Roche aims to prevent bidding war for software firm

January 7, 2011
J.K. Wall
The Swiss company, which operates its North American business out of Indianapolis, filed a lawsuit late last month against Virginia-based Medical Automation Systems Inc. for breaching the purchase agreement the companies signed back in October.
More

Roche acquires Marcadia Biotech

December 30, 2010
Chris O'Malley
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
More

Q&A

December 29, 2010
J.K. Wall
Bruce Frank, a former Roche Diagnostics manager, McKinsey consultant and pro basketball player, talks about changes in the medical device and life sciences industries.
More

Indiana Seed Fund makes 11th investment

December 23, 2010
 IBJ Staff
A $250,000 investment in Aarden Pharmaceuticals will go toward advancing tuberculosis therapy through the pre-clinical development stage.
More

Zimmer looks to China to reignite growth

December 22, 2010
J.K. Wall
Zimmer Holdings Inc. completed an acquisition in China on Tuesday, but recession hangovers in the United States and Europe are trumping all other factors and keeping the company’s growth bottled up for now.
More

Lilly Endowment gives $35M to start pharmacy school

December 20, 2010
J.K. Wall
Manchester College will use money to launch the state's third program offering doctorates in pharmacy.
More

Biomet owners look to arrange $11B marriage

December 15, 2010
J.K. Wall
Warsaw-based Biomet Inc. could get a whole lot bigger if rumors prove true that its owners have made a bid for U.K.-based rival Smith & Nephew plc.
More

State adds record number of life sciences jobs

December 11, 2010
 IBJ Staff
Twenty companies committed this year to add more than 4,000 jobs.
More

Dow AgroSciences moves into new research facility

November 20, 2010
 IBJ Staff
The division of Dow Chemical has a 15-year lease with Indianapolis-based developer Browning Investments on the two-story building near West 96th Street.
More

Medical device maker expanding in Fort Wayne

November 18, 2010
L.H. Medical Corp. said it plans to create up to 65 jobs by 2013 and invest $5.4 million to more than triple the size of its manufacturing operations.
More

Lilly scores series of small victories

November 17, 2010
J.K. Wall
The Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
More

Study: Arthritis drug co-developed by Lilly shows promise

November 12, 2010
 IBJ Staff and Bloomberg News
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
More

Acquisition big step for Lilly Diagnostics

November 10, 2010
J.K. Wall
Eli Lilly and Co.’s $800 million acquisition of Avid Radiopharmaceuticals Inc. is the biggest step yet in the drugmaker’s attempt to add diagnostics to its product portfolio.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...

ADVERTISEMENT